Health technology & biotechnology · Accra, Ghana
We build technology to help biological change be understood earlier, and pursue research into how the body might regain its capacity to heal.
−14% vs baseline
Baseline established
Ready for clinician review
Health results arrive as snapshots. Biology happens over time.
Read one at a time, each result can look fine. Read together, they can show a direction worth noticing.
Our work
A technology platform and a research direction, at different stages and with different aims.
The Early Disease Detection System: an AI-assisted platform being developed to organise and interpret biological information over time.
Research into why some organisms regrow damaged tissue, and the biological conditions that may help mammalian tissue regain regenerative capacity.
What EDDS helps answer
EDDS is being built to answer the questions a single result can't.
Platelets
298 ×10⁹/L
Platelets below personal baseline
−14% vs baseline
Latest result 256 ×10⁹/L. Still inside the population reference range, but outside this person's usual band.
Platelets down, MPV up over the last 3 results
An emerging signal to discuss
Platelet counts have drifted below this person's usual range across the last three results. This is a signal to discuss with a clinician, not a diagnosis.
Meet EDDS
The platform is software and biomarker analysis today. Connected monitoring hardware is the longer-term direction.
Working prototype. Not a clinically validated diagnostic system.
Future monitoring systems must respect privacy, consent and data protection.
Learning from regenerators
Some organisms rebuild tissue that adult mammals cannot. Understanding why is where our research begins.
Regenerate fins, heart tissue and retina throughout adult life.
Can regrow entire limbs and parts of the central nervous system.
In zebrafish, these retinal cells can re-enter the cell cycle and generate new neurons. In mammals, this response is much more limited.
The "immortal jellyfish" can revert from its adult medusa stage to an earlier polyp stage, although it can still die.
Adult mammals keep some of the same cell types, yet rarely mount a regenerative response. We study what may explain that gap.
How we label claims
Every biological claim on this site carries one of three labels, so you know what is known, what we propose, and what still needs testing.
Findings supported by the published scientific literature.
Frameworks and hypotheses that Dimzang is proposing and investigating.
Ideas that remain hypothetical and require experimental validation.
Privacy & consent
EDDS is being designed around a few principles that come before any feature.
Information is used only with the informed consent of the person it belongs to.
Findings are for review by medical experts. EDDS is not an automated diagnosis.
Collect only what is needed, and keep it secure.
These principles are intended to align with Ghana's Data Protection Act, 2012 (Act 843). This website does not collect health information. Privacy Policy
Our team
Researchers, engineers and operators building from Accra and the diaspora.
Founder & CEO · Regenerative medicine research and healthcare systems vision
Head of Administration · Operations and organisational coordination
Chief Technology Officer · EDDS architecture and software development
Partnerships & External Relations · Partnerships and external relations
Research Associate · Biological sciences and laboratory exposure, Noguchi Memorial
Diaspora Research Collaborator · Biochemistry and scientific collaboration support
Legal & Privacy Advisor · Legal and privacy guidance
Partner with us
We work with clinical and research institutions, technology and data partners, investors and collaborators who share our direction.
Help move EDDS from prototype toward structured clinical evaluation.
Start hereWork with us on regenerative biology and computational health questions.
Start hereConnect data sources, devices or infrastructure to the platform.
Start hereSupport the company's growth and long-term direction.
Start hereDimzang Labs is a Ghanaian health technology and biotechnology company based in Accra. We are developing EDDS, an AI-assisted platform for understanding biological change over time, and pursuing research into regenerative biology.
Not yet. EDDS is a working prototype in development. It is not clinically validated and is not available to patients or the public. We are working toward structured clinical evaluation with partners.
No. EDDS is being designed to organise results over time and flag meaningful change for review by medical experts. A flagged change is a signal to discuss, not a diagnosis.
No. Our regenerative medicine work is active research, not a therapy. We do not offer any treatment.
This website does not collect health information, so please don't send any through our forms or email. EDDS is being designed around informed consent, review by medical experts, and collecting only what is needed, in line with Ghana's Data Protection Act, 2012 (Act 843). Privacy Policy.
Tell us about your organisation and what you'd like to explore through the partnership enquiry form. Our team reviews every submission and follows up to start the conversation.
Questions, ideas or introductions: we'd like to hear from you.
